Janssen was seeking to continue its collaboration with Fate Therapeutics with revised terms and conditions. However, Fate Therapeutics chose not to move forward with the partnership. As a result, collaboration activities will wind down in the first quarter of 2023.
Scott Wolchko, President and CEO of Fate Therapeutics, said the following about the news:
“We are disappointed that we were not able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023.”
More Changes Coming to FATE
To go along with this, Fate Therapeutics is adjusting its business. That includes prioritizing clinical programs as well as reducing operating expenses. This will see the company lay off employees to ensure that it has a “three-year cash runway.”
Fate Therapeutics ended Q4 2022 with cash and cash equivalents of $475 million. The job cuts will also see it reduce its workforce to just 220 employees. This should provide the company with enough funds to continue operations through 2025.
Heavy trading has FATE stock falling today as investors sell shares. As of this writing, some 15 million shares have been traded. For comparison, the daily average trading volume is closer to 2.1 million shares.
FATE stock is down 62% as of Friday morning.
Investors looking for more recent stock market news are in luck!
InvestorPlace has all that news ready to go for Friday! A few examples include what has shares of Magic Empire (NASDAQ:MEGL), World Wrestling Entertainment (NYSE:WWE) and Chinese EV stocks moving today. You can get up to speed on all that news at the following links!
More Friday Stock Market News
- Dear MEGL Stock Fans, Mark Your Calendars for Jan. 31
- WWE Stock Gains 17% on Return of Former CEO
- Why Are Chinese EV Stocks NIO, XPEV, LI Down Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.